Last reviewed · How we verify
NCT01380912
Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation?
trial testing methylprednisoloneacetate in Breast Cancer in 160 participants. Status unknown.
1 August 2011
Quick facts
| Lead sponsor | Copenhagen University Hospital at Herlev |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 1 August 2010 |
| Primary completion | 1 August 2011 |
| Estimated completion | 1 August 2012 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
- methylprednisoloneacetate — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Copenhagen University Hospital at Herlev
Who can join
Adults 18 to 90, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
number of punctures
Time frame: 1 month after surgery
Sponsor's own description
A randomised double-blinded study, in which the patients either get methylprednisoloneacetate or saline solution in the mastectomy cavity to evaluate the efficacy of methylprednisoloneacetate in preventing seroma in patients operated for primary breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01380912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Copenhagen University Hospital at Herlev trials
Trials by the same sponsor.
- NCT06802991 — Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0) · NA · recruiting
- NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
- NCT06259279 — High Impact Training to Patients with Prostate Cancer and Bone Metastases · NA · recruiting
- NCT06234306 — Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care · recruiting
- NCT06089551 — Early vs Postponed Parenteral Nutrition After Emergency Abdominal Surgery · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01380912 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Copenhagen University Hospital at Herlev
- Last refreshed: 23 June 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01380912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing